Hang Hubert Yin
Associate Professor

Office: JSCBB A224
Lab: JSCBB A250/260/270/280
Lab Phone: 303-492-8607
 

Education

  • Ph.D.: Yale University (2004)
  • Postdoc: University of Pennsylvania School of Medicine (2004 - 2007)

Areas of Expertise

Bio-Organic, Bio-Inorganic, Cell Signaling, Chemical Biology/Genetics, Membranes, Biophysics, Proteins & Enzymology

Awards and Honors

  • ACS David W. Robertson Award, American Chemical Society (2016)
  • CAPA Distinguished Junior Faculty Award (2012)
  • NSF CAREER Award, National Science Foundation (2010)
  • SU2C IRG Award, Stand Up to Cancer (2010)
  • Gertrude B. Elion Award, American Association for Cancer Research (2009)
  • Early Career Award in Chemistry of Drug Abuse and Addiction, NIDA (2009)
  • New Inventor of the Year, University of Colorado (2009)
  • Cutting-Edge Basic Research Award, NIDA (2009)
  • Collaborative Innovation Award, Howard Hughes Medical Institute (2009)
  • Kimmel Scholars Award, Sidney Kimmel Foundation (2008)
  • Junior Faculty Development Award, University of Colorado (2008)
  • Wood-Whelan Fellowship, International Union of Biochemistry & Mol. Biology (2007)
  • Young Investigator Scholarship, Alzheimer’s Drug Discovery Foundation (2007)
  • Most Cited Paper 2004-2007 Award, Elsevier (2007)

Drug Discovery: Potential Therapeutics that Inhibit Toll-like Receptors

Pain remains a significant public health issue with two-thirds of patients achieving little to no pain relief from the myriad of currently available pharmacotherapies and dosing regimens. The use of opioid (e.g. morphine) pharmacotherapies produces several rewarding and reinforcing side effects, which result in the drugs’ diversion to abuse settings. Glial cells have been found to play a critical role in initiating and maintaining increased nociception in response to peripheral nerve injury. The opioids-induced glial cell activation attenuates opioid-induced pain suppression and enhances the development of opioid tolerance and dependence, the drug reward, and other negative side effects such as respiratory depression. We are interested in employing structure-based drug design and high-throughput screening techniques to identify novel small-molecule inhibitors of TLR4 that regulates glial cell activation. The identified agents will potentially serve as therapeutics that suppresses opioid-dependence and tolerance. Using this method, we also successfully identified small molecule inhibitors that disrupt the TLR3-dsRNA interactions. This is significant because the protein-RNA complex is a challenging target for small molecule probes. Our goal is to develop a generally applicable method to provide small molecule probes for the protein-protein and protein-RNA interactions of these clinically relevant TLRs.

Protein Engineering: Peptides Targeting Transmembrane Domains of Proteins

Protein transmembrane domains (TMDs) regulate many pivotal biological processes, including cell signal transduction, cancer development, ion transmission, and membrane protein folding. However, the molecular recognition in membranes is little understood due to the lack of available probes with high affinity and specificity. Conventional tools such as antibodies are unable to bind to the transmembrane regions of membrane proteins. A second project in our lab is to develop exogenous peptide and small-molecule agents that target transmembrane helices. Using these agents, we can study these important membrane protein-protein interactions, thereby further our understanding of molecular recognition in membranes. As a proof-of-principle, we developed novel peptide/peptidomimetic reagents to recognize the TMDs of latent membrane proteins 1 (LMP-1) found in the human Epstein-Barr herpesvirus lymphomas and syndromes. These designed peptides will be used to study TMD-mediated LMP-1 activation. The findings from these studies will lay the groundwork for the discovery of new pharmaceutical agents with which we can prevent, diagnose, and treat herpesvirus-dependent cancers.

Biotechnology Development: Non-invasive Cancer Biomarkers

Elevated microvesicle (MV) shedding is an indication of cancer metastasis. Sensing their highly curved membrane may provide a novel strategy to detect these MVs, which renders potentials of developing diagnostic, prognostic, and therapeutic agents. We employed a multidisciplinary approach, utilizing our expertise in computational modeling, membrane biophysics, and cellular assay development to rationally design novel tools that sense and regulate membrane curvature and lipid components. These rationally designed agents not only help us to understand the critical protein-lipid interactions but also provide prototypes that may eventually lead to novel cancer biomarkers.

(PubMed search for a full publication list)

  1. Zhang, S.; Hu, Z.; Tanji, H.; Jiang, S.; Das, N.; Li, J.; Sakaniwa, K.; Jin, J.; Bian, Y.; Ohto, U.; Shimizu, T.; Yin, H. “Small Molecule Inhibition of TLR8 through Stabilization of Its Resting State”, Nat. Chem. Biol. 2018, 14, 58-64.
  2. Smith, C. E.; Soti, S.; Jones, T. A.; Nakagawa, A.; Xue, D.; Yin, H. “NSAIDs are Caspase Inhibitors”, Cell Chem. Biol. 2017, 24, 281-292.
  3. Das, N.; Dewan, V.; Grace, P. M.; Gunn, R. J.; Tamura, R.; Tzarum, N.; Watkins, L. R.; Wilson, I. A.; Yin, H. “HMGB-1 Activates Proinflammatory Signaling via TLR5 Leading to Allodynia”, Cell Rep. 2016, 17, 1128-1140.
  4. Yin, H.; Flynn, A.D. “Drugging Membrane Protein Interactions”, Annu. Rev. Biomed. Eng. 2016, 18, 51-76.
  5. Wang, T.; de Jesus, A.; Shi, Y.; Yin, H.; “Pyridoxamine is a substrate of the energy-coupling factor transporter HmpT", Cell Discov. 2015, 1, 15014.
  6. Cheng, K.; Gao, M.; Godfroy, J. I. III; Brown, P. N.; Kastelowitz, N.; *Yin, H.; “Specific Activation of the TLR1-TLR2 Heterodimer by Small-molecule Agonists”, Sci. Adv. 2015, 1, e1400139.